{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T03:14:28Z","timestamp":1778987668725,"version":"3.51.4"},"reference-count":175,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.mehy.2009.01.050","type":"journal-article","created":{"date-parts":[[2009,4,9]],"date-time":"2009-04-09T08:32:38Z","timestamp":1239265958000},"page":"230-250","source":"Crossref","is-referenced-by-count":24,"title":["Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE \u03b54, and hyperhomocysteinemia in neurodegenerative dementias"],"prefix":"10.1016","volume":"73","author":[{"given":"Roger M.","family":"Lane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2009.01.050_bib1","series-title":"The brain cholinergic system in health and disease","article-title":"Cholinergic pathology of the aging - mild cognitive impairment \u2013 Alzheimer\u2019s disease continuum: functional and therapeutic implications","author":"Mesulam","year":"2006"},{"key":"10.1016\/j.mehy.2009.01.050_bib2","first-page":"11","article-title":"Accelerated ageing or selective neuronal loss as an important cause of dementia?","volume":"1","author":"Bowen","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2009.01.050_bib3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/35086072","article-title":"Alzheimer\u2019s disease and Abeta toxicity: from top to bottom","volume":"2","author":"Small","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.mehy.2009.01.050_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.neurobiolaging.2004.02.010","article-title":"Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer\u2019s disease","volume":"25","author":"Klein","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.mehy.2009.01.050_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0306-4522(03)00394-4","article-title":"The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in Alzheimer\u2019s disease-like transgenic mice","volume":"121","author":"Hu","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.mehy.2009.01.050_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.410100203","article-title":"Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis","volume":"10","author":"Whitehouse","year":"1981","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1212\/WNL.54.2.407","article-title":"Cholinergic dysfunction in diseases with Lewy bodies","volume":"54","author":"Tiraboschi","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2009.01.050_bib8","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","article-title":"Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study","volume":"60","author":"Bohnen","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib9","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2174\/138161208784705487","article-title":"The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer\u2019s disease","volume":"14","author":"Deane","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2009.01.050_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.nurt.2008.05.011","article-title":"New therapeutic targets in the neurovascular pathway in Alzheimer\u2019s disease","volume":"5","author":"Zlokovic","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.mehy.2009.01.050_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/nbdi.2001.0462","article-title":"Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain","volume":"9","author":"Mesulam","year":"2002","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.mehy.2009.01.050_bib12","first-page":"6","article-title":"Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action","author":"Poirier","year":"2002","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.mehy.2009.01.050_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/135525704X5553","article-title":"Butyrylcholinesterase: a target in the cholinergic treatment of Alzheimer\u2019s disease","volume":"9","author":"Potkin","year":"2004","journal-title":"Primary Care Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S1461145705005833","article-title":"Targeting acetylcholinesterase and butyrylcholinesterase in dementia","volume":"9","author":"Lane","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2009.01.050_bib15","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.0602922103","article-title":"Butyrylcholinesterase attenuates amyloid fibril formation in vitro","volume":"103","author":"Diamant","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2009.01.050_bib16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1212\/WNL.59.4.563","article-title":"Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months","volume":"59","author":"Darreh-Shori","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2009.01.050_bib17","unstructured":"Giacobini E. Butyrylcholinesterase: its role in brain function. In: Giacobini E, editor. Butyrylcholinesterase: its function and inhibitors. London: Martin Dunitz; 2003. p. 1\u201320."},{"issue":"Suppl. 2","key":"10.1016\/j.mehy.2009.01.050_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00002093-199501002-00005","article-title":"Cholinesterases and the pathology of Alzheimer disease","volume":"9","author":"Geula","year":"1995","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.mehy.2009.01.050_bib19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/ana.410420613","article-title":"Butyrylcholinesterase in the life cycle of amyloid plaques","volume":"42","author":"Guillozet","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib20","article-title":"Butyrylcholinesterase K variant in Alzheimer\u2019s disease","author":"Lehmann","year":"2003"},{"key":"10.1016\/j.mehy.2009.01.050_bib21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrn1035","article-title":"Neurobiology of butyrylcholinesterase","volume":"4","author":"Darvesh","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.mehy.2009.01.050_bib22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00228-003-0716-x","article-title":"Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish population","volume":"59","author":"Babaoglu","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.mehy.2009.01.050_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/FPC.0b013e3282f63f29","article-title":"Synergistic effect of apolipoprotein E \u03b54 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer\u2019s disease","volume":"18","author":"Lane","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.mehy.2009.01.050_bib24","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/mds.21997","article-title":"Lane RM. Rivastigmine vs placebo in hyperhomocysteinemic Parkinson\u2019s disease dementia patients","volume":"23","author":"Barone","year":"2008","journal-title":"Movement Disord"},{"key":"10.1016\/j.mehy.2009.01.050_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1742-4658.2008.06756.x","article-title":"Respective roles of the catalytic domains and C-terminal tail peptides in the oligomerization and secretory trafficking of human acetylcholinesterase and butyrylcholinesterase","volume":"276","author":"Liang","year":"2009","journal-title":"Febs J"},{"key":"10.1016\/j.mehy.2009.01.050_bib26","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00702-006-0526-2","article-title":"Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer\u2019s disease following chronic donepezil treatment","volume":"113","author":"Darreh-Shori","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.mehy.2009.01.050_bib27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000113711","article-title":"Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro","volume":"5","author":"Podoly","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.mehy.2009.01.050_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/CS20000280","article-title":"Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?","volume":"101","author":"Rustemeijer","year":"2001","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.mehy.2009.01.050_bib29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1194\/jlr.R800007-JLR200","article-title":"Role of ganglioside metabolism in the pathogenesis of Alzheimer\u2019s disease \u2013 a review","volume":"49","author":"Ariga","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.mehy.2009.01.050_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.2008.05603.x","article-title":"Lipid peroxidation upregulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer\u2019s disease","author":"Chen","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.mehy.2009.01.050_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF01024921","article-title":"The peptidase activity of human serum butyrylcholinesterase: studies using monoclonal antibodies and characterization of the peptidase","volume":"12","author":"Rao","year":"1993","journal-title":"J Protein Chem"},{"issue":"Pt 1","key":"10.1016\/j.mehy.2009.01.050_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1042\/bj3150127","article-title":"Evidence for a Zn(2+)-binding site in human serum butyrylcholinesterase","volume":"315","author":"Bhanumathy","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.mehy.2009.01.050_bib33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","article-title":"ApoE promotes the proteolytic degradation of Abeta","volume":"58","author":"Jiang","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.mehy.2009.01.050_bib34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00312823","article-title":"Cholinesterases regulate neurite growth of chick nerve cells in vitro by means of a non-enzymatic mechanism","volume":"273","author":"Layer","year":"1993","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.mehy.2009.01.050_bib35","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0014-4886(03)00386-8","article-title":"Effects of acetylcholinesterase and butyrylcholinesterase on cell survival, neurite outgrowth, and voltage-dependent calcium currents of embryonic ventral mesencephalic neurons","volume":"184","author":"Whyte","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1124\/pr.55.2.3","article-title":"The pharmacology of nitric oxide in the peripheral nervous system of blood vessels","volume":"55","author":"Toda","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.mehy.2009.01.050_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0306-4522(00)00335-3","article-title":"Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain","volume":"101","author":"Kasa","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.mehy.2009.01.050_bib38","doi-asserted-by":"crossref","first-page":"11080","DOI":"10.1021\/bi026173d","article-title":"Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer\u2019s disease","volume":"41","author":"Roher","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.mehy.2009.01.050_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.tins.2005.02.001","article-title":"Neurovascular mechanisms of Alzheimer\u2019s neurodegeneration","volume":"28","author":"Zlokovic","year":"2005","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.mehy.2009.01.050_bib40","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nm1287","article-title":"Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease","volume":"11","author":"Wu","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.mehy.2009.01.050_bib41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/BF03033159","article-title":"Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease","volume":"5","author":"Aliev","year":"2003","journal-title":"Neurotox Res"},{"key":"10.1016\/j.mehy.2009.01.050_bib42","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0024-3205(03)00069-9","article-title":"Expression and function of the non-neuronal cholinergic system in endothelial cells","volume":"72","author":"Kirkpatrick","year":"2003","journal-title":"Life Sci"},{"key":"10.1016\/j.mehy.2009.01.050_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1566-0702(02)00263-1","article-title":"The effect of walking on regional blood flow and acetylcholine in the hippocampus in conscious rats","volume":"103","author":"Nakajima","year":"2003","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.mehy.2009.01.050_bib44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00001756-200201210-00020","article-title":"Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer\u2019s disease","volume":"13","author":"Venneri","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.mehy.2009.01.050_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-510X(03)00229-6","article-title":"The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer\u2019s disease and vascular dementia","volume":"216","author":"Lojkowska","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.mehy.2009.01.050_bib46","doi-asserted-by":"crossref","unstructured":"Rosengarten B, Paulsen S, Burr O, Kaps M. Neurovascular coupling in Alzheimer patients: Effect of acetylcholine\u2013esterase inhibitors. Neurobiol Aging 2008.","DOI":"10.1016\/j.neurobiolaging.2008.02.017"},{"key":"10.1016\/j.mehy.2009.01.050_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(00)00903-1","article-title":"Genetic susceptibility factors for Alzheimer\u2019s disease","volume":"412","author":"Richard","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mehy.2009.01.050_bib48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer\u2019s disease: genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1016\/j.mehy.2009.01.050_bib49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0165-0173(98)00008-3","article-title":"The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer\u2019s disease","volume":"27","author":"Beffert","year":"1998","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.mehy.2009.01.050_bib50","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1194\/jlr.M400486-JLR200","article-title":"Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer\u2019s disease","volume":"46","author":"Lane","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.mehy.2009.01.050_bib51","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1073\/pnas.050004797","article-title":"Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer\u2019s disease","volume":"97","author":"Holtzman","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2009.01.050_bib52","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/archneur.55.8.1065","article-title":"Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia","volume":"55","author":"Jonker","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib53","first-page":"1857","article-title":"Dementia, quantitative neuroimaging, and apolipoprotein E genotype","volume":"21","author":"Bigler","year":"2000","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.mehy.2009.01.050_bib54","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/jmg.37.10.766","article-title":"Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer\u2019s disease and in Parkinson\u2019s disease with coexisting Alzheimer pathology","volume":"37","author":"Mattila","year":"2000","journal-title":"J Med Genet"},{"key":"10.1016\/j.mehy.2009.01.050_bib55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0304-3940(98)00453-4","article-title":"Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer\u2019s disease patients","volume":"250","author":"Hiltunen","year":"1998","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.mehy.2009.01.050_bib56","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1034\/j.1600-0404.2000.102006350.x","article-title":"The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer\u2019s disease in women","volume":"102","author":"Alvarez-Arcaya","year":"2000","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.mehy.2009.01.050_bib57","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/hmg\/6.11.1933","article-title":"Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer\u2019s disease","volume":"6","author":"Lehmann","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.mehy.2009.01.050_bib58","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neulet.2004.08.057","article-title":"Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer\u2019s disease","volume":"371","author":"Raygani","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.mehy.2009.01.050_bib59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s004390050929","article-title":"Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer\u2019s disease","volume":"104","author":"Wiebusch","year":"1999","journal-title":"Hum Genet"},{"key":"10.1016\/j.mehy.2009.01.050_bib60","first-page":"219","article-title":"Evidence that the butyrylcholinesterase K variant can protect against late-onset Alzheimer\u2019s disease","volume":"2","author":"Laws","year":"1999","journal-title":"Alzheimer Rep"},{"key":"10.1016\/j.mehy.2009.01.050_bib61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000087065","article-title":"Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer\u2019s disease risk","volume":"20","author":"Combarros","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.mehy.2009.01.050_bib62","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/mds.22357","article-title":"BuChE-K and APOE \u03b54 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline","volume":"24","author":"Lane","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.mehy.2009.01.050_bib63","article-title":"Influence of genetic polymorphisms in the apolipoprotein (APOE) and the butyrylcholinesterase (BCHE) gene on stress markers in older adults: a 3-year study","author":"Fiocco","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.mehy.2009.01.050_bib64","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archneur.55.11.1449","article-title":"Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease","volume":"55","author":"Clarke","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00702-006-0564-9","article-title":"Abeta peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer\u2019s disease","volume":"114","author":"Agnati","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.mehy.2009.01.050_bib66","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1385\/NMM:6:2-3:093","article-title":"Dietary supplementation with 3-deaza adenosine, N-acetyl cysteine, and S-adenosyl methionine provide neuroprotection against multiple consequences of vitamin deficiency and oxidative challenge: relevance to age-related neurodegeneration","volume":"6","author":"Tchantchou","year":"2004","journal-title":"Neuromol Med"},{"key":"10.1016\/j.mehy.2009.01.050_bib67","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1523\/JNEUROSCI.3316-06.2007","article-title":"Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation","volume":"27","author":"Sontag","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.mehy.2009.01.050_bib68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-2005-872394","article-title":"Homocysteine: overview of biochemistry, molecular biology, and role in disease processes","volume":"5","author":"Fowler","year":"2005","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.mehy.2009.01.050_bib69","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1471-4159.2007.04589.x","article-title":"Folate deprivation increases presenilin expression, gamma-secretase activity, and Abeta levels in murine brain: potentiation by ApoE deficiency and alleviation by dietary S-adenosyl methionine","volume":"102","author":"Chan","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.mehy.2009.01.050_bib70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/092986608783330396","article-title":"S-adenosylmethionine inhibits ubiquitin-proteasome system in vitro and on rat vascular smooth muscle cells","volume":"15","author":"D\u2019Anselmi","year":"2008","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.mehy.2009.01.050_bib71","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jn\/134.3.489","article-title":"Glutathione metabolism and its implications for health","volume":"134","author":"Wu","year":"2004","journal-title":"J Nutr"},{"key":"10.1016\/j.mehy.2009.01.050_bib72","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ajcn\/86.3.728","article-title":"Plasma folate concentration and cognitive performance. Rotterdam scan study","volume":"86","author":"de Lau","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.mehy.2009.01.050_bib73","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/hq0701.092000","article-title":"Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide?","volume":"21","author":"Doshi","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.mehy.2009.01.050_bib74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jns.2003.11.009","article-title":"Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity","volume":"218","author":"Gortz","year":"2004","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.mehy.2009.01.050_bib75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000176538","article-title":"Hepatic free choline and betaine and the utilization of dietary protein in the choline-deficient rat","volume":"26","author":"Arvidson","year":"1982","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.mehy.2009.01.050_bib76","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/ajcn\/85.3.702","article-title":"Choline-related supplements improve abnormal plasma methionine\u2013homocysteine metabolites and glutathione status in children with cystic fibrosis","volume":"85","author":"Innis","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.mehy.2009.01.050_bib77","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer\u2019s disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2009.01.050_bib78","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1474-4422(07)70109-6","article-title":"Effect of rivastigmine on delay to diagnosis of Alzheimer\u2019s disease from mild cognitive impairment: the InDDEx study","volume":"6","author":"Feldman","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib79","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/gps.1788","article-title":"A 6-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer\u2019s disease\u2013rivastigmine patch versus capsule","volume":"22","author":"Winblad","year":"2007","journal-title":"Int J Geriatr Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib80","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/01.wnl.0000281847.17519.e0","article-title":"IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease","volume":"69","author":"Winblad","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2009.01.050_bib81","doi-asserted-by":"crossref","unstructured":"Jones R, Schwam E, Wilkinson D, et al. Variation in placebo decline across a decade of Alzheimer\u2019s disease trials. Alzheimer\u2019s and Dementia 2008;4(Suppl 2):T334 [abstract].","DOI":"10.1016\/j.jalz.2008.05.975"},{"key":"10.1016\/j.mehy.2009.01.050_bib82","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000119104","article-title":"A modern hypothesis: the distinct pathologies of dementia associated with Parkinson\u2019s disease versus Alzheimer\u2019s disease","volume":"25","author":"Farlow","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.mehy.2009.01.050_bib83","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/jnnp.2007.127878","article-title":"Amyloid load in Parkinson\u2019s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography","volume":"79","author":"Edison","year":"2008","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib84","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.neurobiolaging.2004.02.002","article-title":"Lethal weapon: amyloid beta-peptide, role in the oxidative stress and neurodegeneration of Alzheimer\u2019s disease","volume":"25","author":"Lahiri","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.mehy.2009.01.050_bib85","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","article-title":"Alzheimer\u2019s disease is a synaptic failure","volume":"298","author":"Selkoe","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.mehy.2009.01.050_bib86","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1212\/01.WNL.0000165987.89198.65","article-title":"Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both","volume":"64","author":"Kraybill","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2009.01.050_bib87","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/01.wnl.0000279520.59792.fe","article-title":"Vascular factors predict rate of progression in Alzheimer disease","volume":"69","author":"Mielke","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2009.01.050_bib88","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-5793(03)00277-1","article-title":"Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease?","volume":"541","author":"Scarpa","year":"2003","journal-title":"FEBS Lett"},{"key":"10.1016\/j.mehy.2009.01.050_bib89","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1192\/bjp.180.2.144","article-title":"Dementia with Lewy bodies","volume":"180","author":"McKeith","year":"2002","journal-title":"Brit J Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib90","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archpsyc.62.5.565","article-title":"Variability of familial risk of Alzheimer disease across the late life span","volume":"62","author":"Silverman","year":"2005","journal-title":"Arch Gen Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib91","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archneur.63.2.189","article-title":"Apolipoprotein E and dementia in Parkinson disease: a meta-analysis","volume":"63","author":"Huang","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib92","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1212\/01.wnl.0000326146.60732.d6","article-title":"Imaging amyloid deposition in Lewy body diseases","volume":"71","author":"Gomperts","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2009.01.050_bib93","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1185\/03007990802328142","article-title":"Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study","volume":"24","author":"Ballard","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mehy.2009.01.050_bib94","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","article-title":"Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials","volume":"6","author":"Kavirajan","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib95","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(95)91411-0","article-title":"ApoE genotype and survival from intracerebral haemorrhage","volume":"346","author":"Alberts","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2009.01.050_bib96","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1468-1331.2000.00046.x","article-title":"An efficacy and safety analysis of Exelon in Alzheimer\u2019s disease patients with concurrent vascular risk factors","volume":"7","author":"Kumar","year":"2000","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib97","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1742-1241.2002.tb11377.x","article-title":"Rivastigmine in patients with Alzheimer\u2019s disease and concurrent hypertension","volume":"56","author":"Erkinjuntti","year":"2002","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.mehy.2009.01.050_bib98","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2009.01.050_bib99","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","article-title":"Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial","volume":"34","author":"Black","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.mehy.2009.01.050_bib100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/01.WNL.0000078943.50032.FC","article-title":"Donepezil in vascular dementia: a randomized, placebo-controlled study","volume":"61","author":"Wilkinson","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2009.01.050_bib101","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.clinbiochem.2007.04.007","article-title":"Relations between homocysteine, folate and vitamin B12 in vascular dementia and in Alzheimer disease","volume":"40","author":"Koseoglu","year":"2007","journal-title":"Clin Biochem"},{"key":"10.1016\/j.mehy.2009.01.050_bib102","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1161\/01.STR.0000032550.90046.38","article-title":"Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland","volume":"33","author":"McIlroy","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.mehy.2009.01.050_bib103","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2009.01.050_bib104","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejphar.2007.06.053","article-title":"N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine","volume":"572","author":"Cerbai","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mehy.2009.01.050_bib105","series-title":"Recent progress in Alzheimer\u2019s and Parkinson\u2019s diseases","first-page":"33","article-title":"Acetylcholinesterase, cholinergic signaling and Parkinson\u2019s disease","author":"Ben-Shaul","year":"2005"},{"key":"10.1016\/j.mehy.2009.01.050_bib106","doi-asserted-by":"crossref","first-page":"10670","DOI":"10.1523\/JNEUROSCI.1987-04.2004","article-title":"Interactions between GABAergic and cholinergic processes in the nucleus pontis oralis: neuronal mechanisms controlling active (rapid eye movement) sleep and wakefulness","volume":"24","author":"Xi","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.mehy.2009.01.050_bib107","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.brainresbull.2006.03.002","article-title":"Antioxidant response analysis in the brain after pilocarpine treatments","volume":"69","author":"Tejada","year":"2006","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.mehy.2009.01.050_bib108","doi-asserted-by":"crossref","first-page":"35785","DOI":"10.1074\/jbc.M602799200","article-title":"A functional transsulfuration pathway in the brain links to glutathione homeostasis","volume":"281","author":"Vitvitsky","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2009.01.050_bib109","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.freeradbiomed.2005.12.023","article-title":"Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson\u2019s disease","volume":"40","author":"Chinta","year":"2006","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.mehy.2009.01.050_bib110","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/jnr.20394","article-title":"Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1\u201342)-mediated oxidative stress and neurotoxicity: implications for Alzheimer\u2019s disease","volume":"79","author":"Boyd-Kimball","year":"2005","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.mehy.2009.01.050_bib111","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000080966","article-title":"Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression","volume":"19","author":"Andin","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.mehy.2009.01.050_bib112","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1523\/JNEUROSCI.22-05-01752.2002","article-title":"Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer\u2019s disease","volume":"22","author":"Kruman","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.mehy.2009.01.050_bib113","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0925-4439(99)00010-1","article-title":"Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury","volume":"1453","author":"Lomnitski","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.mehy.2009.01.050_bib114","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/187569208784017494","article-title":"Pharmacogenenomics and the treatment of Sporadic Alzheimer\u2019s disease: a decade of progress","volume":"6","author":"Poirier","year":"2008","journal-title":"Curr Pharmacogenom Personalize Med"},{"key":"10.1016\/j.mehy.2009.01.050_bib115","doi-asserted-by":"crossref","unstructured":"Nizri E, Irony-Tur-Sinai M, Faranesh N, et al. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 2008.","DOI":"10.1016\/j.jneuroim.2008.06.018"},{"key":"10.1016\/j.mehy.2009.01.050_bib116","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0140-6736(06)68542-5","article-title":"Mild cognitive impairment","volume":"367","author":"Gauthier","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2009.01.050_bib117","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa050151","article-title":"Vitamin E and donepezil for the treatment of mild cognitive impairment","volume":"352","author":"Petersen","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.mehy.2009.01.050_bib118","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1212\/01.wnl.0000303815.69777.26","article-title":"Safety and efficacy of galantamine in subjects with mild cognitive impairment","volume":"70","author":"Winblad","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2009.01.050_bib119","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.wad.0000127445.00442.a1","article-title":"Disease stage in Alzheimer disease and treatment effects of rivastigmine","volume":"18","author":"Kurz","year":"2004","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.mehy.2009.01.050_bib120","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/(SICI)1096-9861(19980413)393:3<374::AID-CNE8>3.0.CO;2-Z","article-title":"Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation","volume":"393","author":"Darvesh","year":"1998","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib121","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cne.10751","article-title":"Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus","volume":"463","author":"Darvesh","year":"2003","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib122","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s007020200089","article-title":"Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer\u2019s disease by rivastigmine: correlation with cognitive benefit","volume":"109","author":"Giacobini","year":"2002","journal-title":"J Neural Transm"},{"key":"10.1016\/j.mehy.2009.01.050_bib123","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/156720507781077313","article-title":"Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase","volume":"4","author":"Bullock","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.mehy.2009.01.050_bib124","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00008571-200304000-00008","article-title":"Regulation of attention and response to therapy in dementia by butyrylcholinesterase","volume":"13","author":"O\u2019Brien","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.mehy.2009.01.050_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.993","article-title":"Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson\u2019s disease","volume":"19","author":"Leroi","year":"2004","journal-title":"Int J Geriatr Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib126","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","article-title":"Donepezil for cognitive impairment in Parkinson\u2019s disease: a randomised controlled study","volume":"72","author":"Aarsland","year":"2002","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib127","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","article-title":"Donepezil for dementia in Parkinson\u2019s disease: a randomised, double blind, placebo controlled, crossover study","volume":"76","author":"Ravina","year":"2005","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib128","doi-asserted-by":"crossref","unstructured":"Dubois B, Tolosa E, Kulisevsky J, et al. Efficacy and safety of donepezil in the treatment of Parkinson\u2019s disease patients with dementia. In: 8th international conference on Alzheimer\u2018s and Parkinson\u2019s diseases. Salzburg, Austria; 2007.","DOI":"10.1037\/e698632007-001"},{"key":"10.1016\/j.mehy.2009.01.050_bib129","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","article-title":"Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study","volume":"356","author":"McKeith","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2009.01.050_bib130","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease","volume":"351","author":"Emre","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.mehy.2009.01.050_bib131","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/mds.21077","article-title":"Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson\u2019s disease","volume":"21","author":"Burn","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.mehy.2009.01.050_bib132","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bcp.2005.05.019","article-title":"Brain cholinergic vulnerability: relevance to behavior and disease","volume":"70","author":"McKinney","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.mehy.2009.01.050_bib133","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1749-6632.1991.tb00217.x","article-title":"Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson\u2019s disease, and Alzheimer\u2019s disease","volume":"640","author":"Perry","year":"1991","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.mehy.2009.01.050_bib134","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/030079905X56565","article-title":"Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer\u2019s disease over a 2-year period","volume":"21","author":"Bullock","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mehy.2009.01.050_bib135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079906X80279","article-title":"Response to rivastigmine or donepezil in Alzheimer\u2019s patients with symptoms suggestive of concomitant Lewy body pathology","volume":"22","author":"Touchon","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mehy.2009.01.050_bib136","first-page":"285","article-title":"Effects of cholinesterase inhibition on brain white matter volume in Alzheimer\u2019s disease","volume":"20","author":"Venneri","year":"2009","journal-title":"Neuro Report"},{"key":"10.1016\/j.mehy.2009.01.050_bib137","unstructured":"Ferris S, Lane R, Sfikas N, Winblad B, Farlow M, Feldman H. Treatment response to rivastigmine in mild cognitive impairment: an enhanced statistical modeling approach. Gender Medicine; in press."},{"key":"10.1016\/j.mehy.2009.01.050_bib138","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.fpc.0000220573.05714.ac","article-title":"Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer\u2019s disease","volume":"16","author":"Blesa","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.mehy.2009.01.050_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-008-1092-0","article-title":"Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme","volume":"198","author":"Schaeffer","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.mehy.2009.01.050_bib140","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1212\/01.wnl.0000261920.03297.64","article-title":"Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies","volume":"68","author":"Ballard","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2009.01.050_bib141","unstructured":"Kuljis RO, Farlow M, Grossberg G. Long-term exposure to rivastigmine may reduce senile plaque density. In: Society for neuroscience. Washington DC, USA; 2003."},{"key":"10.1016\/j.mehy.2009.01.050_bib142","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.brainres.2005.08.039","article-title":"Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer\u2019s plaques and tangles","volume":"1060","author":"Eskander","year":"2005","journal-title":"Brain Res"},{"key":"10.1016\/j.mehy.2009.01.050_bib143","doi-asserted-by":"crossref","first-page":"117","DOI":"10.55782\/ane-2005-1544","article-title":"Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer\u2019s disease","volume":"65","author":"Sobow","year":"2005","journal-title":"Acta Neurobiol Exp (Wars)"},{"issue":"1","key":"10.1016\/j.mehy.2009.01.050_bib144","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/156720509787313961","article-title":"Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients","volume":"6","author":"Nordberg","year":"2009","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.mehy.2009.01.050_bib145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00002826-200405000-00011","article-title":"Acetylcholinesterase and its inhibition in Alzheimer disease","volume":"27","author":"Lane","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.mehy.2009.01.050_bib146","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0304-3940(02)01384-8","article-title":"Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1\u201342 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients","volume":"338","author":"Stefanova","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.mehy.2009.01.050_bib147","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0928-4257(99)80002-3","article-title":"Molecular interactions of acetylcholinesterase with senile plaques","volume":"92","author":"Inestrosa","year":"1998","journal-title":"J Physiol Paris"},{"key":"10.1016\/j.mehy.2009.01.050_bib148","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0006-2952(02)01514-9","article-title":"Beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies","volume":"65","author":"Bartolini","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.mehy.2009.01.050_bib149","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nbd.2003.08.014","article-title":"Acetylcholinesterase induces the expression of the beta-amyloid precursor protein in glia and activates glial cells in culture","volume":"14","author":"von Bernhardi","year":"2003","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.mehy.2009.01.050_bib150","doi-asserted-by":"crossref","first-page":"10447","DOI":"10.1021\/bi0101392","article-title":"A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation","volume":"40","author":"De Ferrari","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.mehy.2009.01.050_bib151","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/brain\/awm276","article-title":"Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology","volume":"131","author":"Berson","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.mehy.2009.01.050_bib152","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0278-5846(01)00326-8","article-title":"Long-term effects of rivastigmine in moderately severe Alzheimer\u2019s disease: does early initiation of therapy offer sustained benefits?","volume":"26","author":"Doraiswamy","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib153","first-page":"61","article-title":"Mechanisms of action and treatment benefits with cholinesterase inhibitors with vascular cognitive disorders","volume":"8","author":"Erkinjuntti","year":"2005","journal-title":"J Drug Assess"},{"key":"10.1016\/j.mehy.2009.01.050_bib154","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00001756-200502080-00006","article-title":"Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer\u2019s disease","volume":"16","author":"Venneri","year":"2005","journal-title":"Neuroreport"},{"key":"10.1016\/j.mehy.2009.01.050_bib155","series-title":"Recent progress in Alzheimer\u2019s and Parkinson\u2019s diseases","first-page":"33","article-title":"Acetylcholinesterase, cholinergic signaling and Parkinson\u2019s disease","author":"Ben-Shaul","year":"2005"},{"key":"10.1016\/j.mehy.2009.01.050_bib156","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0006-8993(01)02653-1","article-title":"Effects of ENA713 and CHF2819, two anti-Alzheimer\u2019s disease drugs, on rat amino acid levels","volume":"910","author":"Trabace","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.mehy.2009.01.050_bib157","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0020-711X(93)90589-7","article-title":"Inhibition kinetics of brain butyrylcholinesterase by Cd2+ and Zn2+, Ca2+ or Mg2+ reactivates the inhibited enzyme","volume":"25","author":"Cokugras","year":"1993","journal-title":"Int J Biochem"},{"key":"10.1016\/j.mehy.2009.01.050_bib158","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0167-4838(98)00104-6","article-title":"Butyrylcholinesterase-catalysed hydrolysis of aspirin, a negatively charged ester, and aspirin-related neutral esters","volume":"1387","author":"Masson","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.mehy.2009.01.050_bib159","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pharmthera.2006.07.001","article-title":"Lipoic acid as a novel treatment for Alzheimer\u2019s disease and related dementias","volume":"113","author":"Holmquist","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.mehy.2009.01.050_bib160","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/aje\/kwi259","article-title":"Homocysteine and cognitive performance in the Framingham offspring study: age is important","volume":"162","author":"Elias","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.mehy.2009.01.050_bib161","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0140-6736(07)60109-3","article-title":"Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial","volume":"369","author":"Durga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2009.01.050_bib162","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/gps.388","article-title":"Improvement of cognitive functions after cobalamin\/folate supplementation in elderly patients with dementia and elevated plasma homocysteine","volume":"16","author":"Nilsson","year":"2001","journal-title":"Int J Geriatr Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib163","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","article-title":"High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial","volume":"300","author":"Aisen","year":"2008","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.mehy.2009.01.050_bib164","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/gps.1856","article-title":"A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer\u2019s disease","volume":"23","author":"Connelly","year":"2008","journal-title":"Int J Geriatr Psychiat"},{"key":"10.1016\/j.mehy.2009.01.050_bib165","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1212\/WNL.57.8.1515","article-title":"Controlled trial of N-acetylcysteine for patients with probable Alzheimer\u2019s disease","volume":"57","author":"Adair","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2009.01.050_bib166","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/glia.20185","article-title":"Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons","volume":"51","author":"Huang","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.mehy.2009.01.050_bib167","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00228-006-0132-0","article-title":"Tolcapone decreases plasma levels of S-adenosyl-l-homocysteine and homocysteine in treated Parkinson\u2019s disease patients","volume":"62","author":"Muller","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.mehy.2009.01.050_bib168","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.WNF.0000220817.94102.95","article-title":"The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status","volume":"29","author":"Zesiewicz","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.mehy.2009.01.050_bib169","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2165\/00002512-200522080-00005","article-title":"Causes of syncope in patients with Alzheimer\u2019s disease treated with donepezil","volume":"22","author":"Bordier","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.mehy.2009.01.050_bib170","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1136\/jnnp.74.9.1294","article-title":"Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension","volume":"74","author":"Singer","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mehy.2009.01.050_bib171","unstructured":"Eisai. Eisai reports results from latest donepezil study in vascular dementia (news release, March 16, 2006). In: <http:\/\/www.eisai.co.jp\/enews\/enews200609.html>; 2007 [accessed July 17, 2007]."},{"key":"10.1016\/j.mehy.2009.01.050_bib172","first-page":"639","article-title":"Cardiac safety of rivastigmine in Lewy body and Parkinson\u2019s disease dementias","volume":"60","author":"Ballard","year":"2006","journal-title":"IJCP"},{"key":"10.1016\/j.mehy.2009.01.050_bib173","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s004150070147","article-title":"The two faces of Alzheimer\u2019s disease","volume":"247","author":"van Gool","year":"2000","journal-title":"J Neurol"},{"key":"10.1016\/j.mehy.2009.01.050_bib174","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine-reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.mehy.2009.01.050_bib175","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JAD-2007-11412","article-title":"Rivastigmine in dementia associated with Parkinson\u2019s disease and Alzheimer\u2019s disease: similarities and differences","volume":"11","author":"Emre","year":"2007","journal-title":"J Alzheimers Dis"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987709001443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987709001443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T14:08:21Z","timestamp":1710252501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987709001443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":175,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0306987709001443"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2009.01.050","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}